Loading
ResMed Inc Stock: price and insider trades · United States
ResMed Inc: what insiders have been doing
Headquartered in San Diego, United States, ResMed Inc belongs to the Healthcare & Pharma sector and traces its origins to 1989. Filings by its managers are published through SEC (Form 4). 17 insiders have disclosed 63 filings since 18 October 2025.
There is no open-market purchase to report; the filings show 23 sales worth €10.3M by 5 insiders. The totals do not cover 1 filing with an undisclosed amount. Farrell Peter C filed the largest sale, €1.6M, on 6 August 2026, which represents 0.0054% of the company's market value.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
With 63 filings in twelve months, the company is more active than the median of 19 filings across the 5,808 companies we follow on the same exchange. Since 2016, the database holds no purchases and 147 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 30 June 2026 lists revenue at 5.65 bn USD and net income at 1.52 bn USD; the dividend was 2.40 USD per share.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
398
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€64M
147 ops. · all time
Who traded when
BuySalePeter C. Farrell16 sales
Brett Sandercock13 sales
Michael J. Rider12 sales
Michael J. Farrell6 sales
De Witte Jan4 sales
Justin Leong1 sale
Analyst consensus: bullish or bearish?
Analysts rate ResMed Inc Buy (bullish), based on 17 analysts. Average price target: US$250.52.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 3,846 of 24,148 companies
69.3
score / 100
Value53
Quality86
FCF yld4.8%
Earn yld4.5%
EV/EBITDA16.0x
ROE24%
Gross mgn61%
Net mgn27%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended June 2026 · cache
US$235.29
Analyst consensus
17 analystsBuy
US$175.00Target US$250.52(+6%)US$320.00
Income statement
RevenueUS$5.7B
Gross profitUS$3.5B61% margin
EBITDAUS$2.2B38% margin
Net incomeUS$1.5B26.9% margin
Valuation
PER (trailing)22.5x
PER (forward)17.8x
P/Book5.2x
Beta0.75
Balance sheet & cash
Market capUS$33.1B
Total debtUS$825.9M
Free Cash FlowUS$1.6B
Debt / Equity13%
Profitability & ownership
ROE24.3%
ROA14.0%
% insiders0.5%
% institutions73.0%
Last declaration on 8 October 2026
Declarations398 total
4,991 shares@ US$226.33490.0035% mcap1.8% of flowResMed Common StockSEC:0000943819-26-000085:1
4,991 shares@ US$146.340.0023% mcap1.2% of flowResMed Common StockSEC:0000943819-26-000085:0
4,991 shares@ US$226.33490.0035% mcap1.9% of flowCommonSEC144:0001959173-26-007310
3,230 shares0ResMed Common StockSEC:0000943819-26-000076:0
9,072 shares0ResMed Common StockSEC:0000943819-26-000073:0
6,461 shares0ResMed Common StockSEC:0000943819-26-000077:0
13,547 shares0ResMed Common StockSEC:0000943819-26-000075:0
4,991 shares@ US$146.340.0022% mcap1.2% of flowResMed Common StockSEC:0000943819-26-000052:0
4,991 shares@ US$222.43850.0033% mcap1.8% of flowResMed Common StockSEC:0000943819-26-000052:1
4,991 shares@ US$226.220.0034% mcap1.8% of flowCommonSEC144:0001959173-26-006784
970 shares@ US$234.730.0007% mcap1.4% of flowResMed Common StockSEC:0000943819-26-000050:0
4,991 shares@ US$205.68950.0031% mcap1.7% of flowResMed Common StockSEC:0000943819-26-000043:1
4,991 shares@ US$146.340.0022% mcap1.2% of flowResMed Common StockSEC:0000943819-26-000043:0
4,991 shares@ US$205.68950.0031% mcap1.7% of flowCommonSEC144:0001959173-26-005734
8,000 shares@ US$225.000.0054% mcap10.8% of flowResMed Common StockSEC:0000943819-26-000040:0
8,000 shares@ US$224.95540.0054% mcap100.0% of flowCommonSEC144:0001628280-26-053728
4,991 shares@ US$146.340.0022% mcap1.2% of flowResMed Common StockSEC:0000943819-26-000038:0
4,991 shares@ US$218.54750.0033% mcap1.8% of flowResMed Common StockSEC:0000943819-26-000038:1
4,991 shares@ US$219.340.0033% mcap1.8% of flowCommonSEC144:0001959173-26-005132
4,991 sharesResMed Common StockSEC:0000943819-26-000035:0
4,991 sharesResMed Common StockSEC:0000943819-26-000035:1
4,991 shares@ US$194.000.0030% mcap1.6% of flowCommonSEC144:0001959173-26-004405
4,991 shares@ US$146.341.2% of flowResMed Common StockSEC:0000943819-26-000021:0
4,991 shares@ US$225.50321.8% of flowResMed Common StockSEC:0000943819-26-000021:1
1,000 shares@ US$224.310.9% of flowResMed Common StockSEC:0000943819-26-000020:0
25 of 398 declarations
About ResMed Inc
Resmed Inc. (ticker RSMDF) is a global health technology company focused on sleep, breathing, and home-based care. The company is listed on the U.S. NYSE under the symbol RMD, and its headquarters are in San Diego, California, United States. Resmed was founded in 1989 in Australia by Dr. Peter Farrell, initially built around positive airway pressure therapy for sleep apnea, and has since evolved into an international connected-health platform spanning medical devices, software, and digital patient engagement. ([resmed.com](https://www.resmed.com/en-us/about-us/history/?utm_source=openai))
Resmed’s business model is centered on diagnosing, treating, and monitoring sleep and respiratory disorders, especially obstructive sleep apnea and COPD. Its portfolio includes CPAP devices, ventilators, masks, accessories, cloud-connected monitoring tools, and software platforms used by patients, clinicians, and home-care providers. The company emphasizes an integrated approach that combines hardware, digital health software, and care-management solutions, with a clear focus on moving more care out of the hospital and into the home. ([resmed.com](https://www.resmed.com/en-us/about-us/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Resmed is one of the leading global players in sleep-apnea treatment and home respiratory care. Its international footprint is broad, with management and corporate materials describing operations in more than 140 countries, which gives the company geographic diversification and exposure to both mature and emerging healthcare markets. That scale matters because Resmed’s business benefits from recurring demand for replacement masks, accessories, ongoing patient monitoring, and software-enabled workflow tools. ([investor.resmed.com](https://investor.resmed.com/?utm_source=openai))
Key product families include AirSense and AirCurve devices, AirFit and AirTouch masks, and digital solutions such as myAir. Resmed has also expanded its diagnosis and care pathway capabilities. In April 2025, it launched NightOwl home sleep apnea testing across the United States, and in May 2025 it acquired VirtuOx, an independent diagnostic testing facility specializing in sleep, respiratory, and cardiac conditions. In December 2025, the company announced FDA clearance for Smart Comfort, an AI-enabled feature designed to personalize CPAP comfort settings and help patients start and stay on therapy. ([investor.resmed.com](https://investor.resmed.com/news-events/press-releases/detail/399/resmed-announces-small-easy-to-use-home-sleep-apnea-test-nightowl-now-available-across-the-us?utm_source=openai))
Recent financial updates point to solid momentum. For the first quarter of fiscal 2026, Resmed reported revenue growth of 9% to $1.34 billion, alongside margin expansion and continued operating leverage. For fiscal 2025, the company reported annual revenue of $5.1 billion, up 10% year over year, reinforcing the strength of demand for its sleep-health and breathing-health solutions. For francophone investors, Resmed offers a combination of healthcare defensiveness, recurring revenue characteristics, and a growth profile increasingly supported by digital health innovation. ([newsroom.resmed.com](https://newsroom.resmed.com/news-releases/news-details/2025/Resmed-Inc--Announces-Results-for-the-First-Quarter-of-Fiscal-Year-2026/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
